Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 5, 2007, Pages 874-879

  Glocker, Erik ^a,b   Bogdan, Christian ^a   Kist, Manfred ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Antibiotic resistance; Mutations; Rifabutin; RpoB

Indexed keywords

AMINO ACID; AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; TETRACYCLINE;

AMINO ACID SUBSTITUTION; ANALYTICAL EQUIPMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CODON; CONTROLLED STUDY; CROSS RESISTANCE; GENETIC SELECTION; GENETIC VARIABILITY; GERMANY; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; GERMANY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTATION; RIFABUTIN; RIFAMPIN; STOMACH;

EID: 34447575705     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm039     Document Type: Article

References (20)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.
2. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 6370-8.
3. Malfertheiner P, Mégraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-9.
4. Perri F, Festa V, Clemente R et al. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimen. Aliment Pharmacol Ther 2001; 14: 311-6.
5. Gisbert JP, Pajares JM. Helicobacter pylorí 'rescue' therapy after failure of two eradication treatments. Helicobacter 2005; 10 363-72.
6. Toracchio S, Capodicasa S, Soraja DB et al. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33-8.
7. Kunin CM. Antimicrobial activity of rifabutin. Clin Infect Dis 1996; 22 (Suppl. 1): S3-13.
8. Heep M, Beck D, Bayerdoerffer E et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1497-9.
9. Heep M, Rieger U, Beck D et al. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 1075-7.
10. Wang G, Wilson TJ, Jiang Q et al. Spontaneous mutations that confer antibiotic resistance in Helibobacter pylori. Antimicrob Agents Chemother 2001; 45: 727-33.
11. Heep M, Lehn N, Brandstaetter B et al. Detection of rifabutin resistance and association of rpoB mutations with resistance to four rifamycin derivatives in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 143-5.
12. Kist M. Díagnostische Verfahrensdchtlinien der DGHM: Isolierung und Identifizierung von Bakterien der Gattungen Campylobacter und Helicobacter. Zentralbl Bakteriol 1991; 276: 124-39.
13. Strobel S, Bereswill S, Balig P et al. Identification and analysis of a new vacA genotype variant of Helicobacter pylori in different patient groups in Germany. J Clin Microbiol 1998; 36 1285-90.
14. Glupczynski Y, Mégraud F, Lopez-Brea M et al. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
15. Cederbrant G, Kahlmeter G, Ljungh A. The Etest for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 1993; 31: 65-71.
16. Shimada A. PCR-based site-directed mutagenesis. Methods Mol Biol 1996; 57: 157-65.
17. Gerrits MM, Beming M, Van Vliet AHM et al. Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003; 47: 2984-6.
18. Wang Y, Roos KP, Taylor DE. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker. J Gen Microbiol 1993; 139: 2485-93.
19. Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388 539-47.
20. Williams DL, Spring L, Collins L et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42 1853-7.